PhD Tihomir Tomašić

PhD Tihomir Tomašić
no.: 28334 source: ARIS

researcher – active in research organisation
  tihomir.tomasicat signffa.uni-lj.si
  • English
  • Reading: Fluent
  • Writing: Fluent
  • Speaking: Fluent
  • Croatian
  • Reading: Functional
  • Writing: Functional
  • Speaking: Functional
  • German
  • Reading: Functional
  • Writing: Basic
  • Speaking: Functional
Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   

Code Science Field
B740  Biomedical sciences  Pharmacological sciences, pharmacognosy, pharmacy, toxicology 
B200  Biomedical sciences  Cytology, oncology, cancerology 
B230  Biomedical sciences  Microbiology, bacteriology, virology, mycology 
Keywords
drug design; inhibitor; molecular modelling; DNA gyrase; Hsp90; antibacterial activity; anticancer activity
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
1,295.44
A''
198.73
A'
691.31
A1/2
912.71
CI10
2,606
CImax
193
h10
27
A1
4.65
A3
0.71
Data for the last 5 years (citations for the last 10 years) on October 15, 2025; Data for score A3 calculation refer to period 2020-2024 (2019, 2020)
Data for ARIS tenders ( 23.05.2022 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 135  3,141  2,553  18.91 
Scopus 137  3,486  2,844  20.76 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 PhD Jaka Dernovšek   Bologna doctoral studies  10/1/2020 - 9/30/2024  54784 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
  B. Sc.     SI University of Ljubljana, Faculty of Pharmacy 2006 
Doctoral degree  Ph. D.     SI University of Ljubljana, Faculty of Pharmacy 2011 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group Date of employment Position Role Title
Full time employment (120%, RD:50%)  University of Ljubljana, Faculty of Pharmacy  Chair for Pharmaceutical Chemistry  11/1/2006  Professor  Researcher  Full professor 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. N1-0331  A double whammy for the NF-κB signalling pathway: development of TAK1 and IKKβ degraders against inflammation-driven diseases   1/1/2024 - 12/31/2027  PhD Izidor Sosič   1,086 
2. J1-50038  New Hsp90 Inhibitor-based Therapies for Ewing Sarcoma   1/1/2024 - 12/31/2026  PhD Tihomir Tomašić   1,206 
3. J1-50023  3DfluorCO - Three-dimensional fluorine-based carbonyl bioisosteres: asymmetric synthesis and validation   10/1/2023 - 9/30/2026  PhD Andrej Emanuel Cotman   1,199 
4. J1-50037  Development of CDK1-selective degraders for the treatment of T-cell malignancies   10/1/2023 - 9/30/2026  PhD Izidor Sosič   1,278 
5. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   10/1/2022 - 9/30/2026  PhD Lucija Peterlin Mašič   6,640 
6. BI-US/24-26-033  Unraveling Hsp90 inhibitor binding modes for rational anticancer drug design   7/1/2024 - 6/30/2026  PhD Tihomir Tomašić   432 
7. J1-4400  Evaluation of transient protein states   10/1/2022 - 9/30/2025  PhD Simona Golič Grdadolnik   3,481 
8. J3-4496  Next-generation adjuvants for mucosal vaccines   10/1/2022 - 9/30/2025  PhD Žiga Jakopin   1,414 
9. J1-3031  Development of new inhibitors of bacterial topoisomerases to overcome antimicrobial resistance   10/1/2021 - 9/30/2025  PhD Nace Zidar   1,158 
10. J1-3030  MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance   10/1/2021 - 9/30/2025  PhD Lucija Peterlin Mašič   1,070 
11. BI-HR/23-24-032  Evaluation of harmine analogues as potential Hsp90 inhibitors against pediatric sarcomas   4/1/2023 - 3/31/2025  PhD Tihomir Tomašić   432 
12. BI-AT/23-24-008  Development of Hsp90 C-terminal domain inhibitors for the treatment of pediatric sarcomas   1/1/2023 - 12/31/2024  PhD Tihomir Tomašić   432 
13. J3-2517  Development of innate immune receptor-targeting chimeras as custom-tailored vaccine adjuvants   9/1/2020 - 12/31/2023  PhD Žiga Jakopin   2,442 
14. J1-2483  Radiopharmaceuticals with antagonistic activity on CCK2R   9/1/2020 - 8/31/2023  PhD Marko Anderluh   1,164 
15. J1-2485  The kiss of death for key apoptosis players: development of BCL-2 and BAX PROTACs   9/1/2020 - 8/31/2023  PhD Izidor Sosič   1,100 
16. J1-1717  Development of novel Hsp90 inhibitors with anticancer activity   7/1/2019 - 6/30/2023  PhD Tihomir Tomašić   2,064 
17. N1-0098  Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity   1/1/2019 - 12/31/2022  PhD Lucija Peterlin Mašič   979 
18. J3-9256  Development of NOD2 agonists and dual NOD2/TLR7 agonistic conjugates as novel vaccine adjuvants   7/1/2018 - 6/30/2022  PhD Žiga Jakopin   3,048 
19. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   7/1/2018 - 6/30/2021  PhD Lucija Peterlin Mašič   2,420 
20. J1-8140  Endokrini in genotoksični potencial inhibitorjev proteinskih kinaz: pomen za tveganja za okolje in zdravje ljudi (Slovene)   5/1/2017 - 4/30/2020  PhD Metka Filipič   4,032 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2022 - 12/31/2027 PhD Stanislav Gobec   5,846 
2. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2015 - 12/31/2021 PhD Stanislav Gobec   6,517 
3. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2009 - 12/31/2014 PhD Danijel Kikelj   6,386 
4. P1-0208  Medicinal chemistry - drug design, synthesis and evaluation   1/1/2004 - 12/31/2008 PhD Danijel Kikelj   6,446 
International projects
no. Code Title Period Head
1. CELSA/23/031  Exploiting structural insights in IP3 receptor function to develop novel, allosteric inhibitors of IP3 receptor channels (SINFONIC)   10/1/2023 - 9/30/2025    
2. COST-CA15135  Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)   4/18/2016 - 4/17/2020    
3. COST-CM1307  Targeted chemotherapy towards diseases caused by endoparasites   3/12/2014 - 3/11/2018    
Confirmation required
Views history
Favourite